DDInter305 DDInter1376
Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension. Carvedilol was granted FDA approval on 14 September 1995.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Carvedilol {u} (Compound) resembles {v} (Compound) Propafenone
Carvedilol {u} (Compound) resembles {v} (Compound) Bopindolol
Carvedilol {u} (Compound) treats {v} (Disease) hypertension
Carvedilol {u} (Compound) binds {v} (Gene) CYP1A1
Carvedilol {u} (Compound) upregulates {v} (Gene) INSIG1
Carvedilol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta1-Antagonists
Carvedilol {u} (Compound) downregulates {v} (Gene) CDC20
Carvedilol {u} (Compound) causes {v} (Side Effect) Angina unstable
Carvedilol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Kaolin
Carvedilol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Levothyroxine
Carvedilol (Compound) resembles Propafenone (Compound)
Carvedilol (Compound) resembles Bopindolol (Compound)
Carvedilol (Compound) treats hypertension (Disease)
Carvedilol (Compound) binds CYP1A1 (Gene)
Carvedilol (Compound) upregulates INSIG1 (Gene)
Carvedilol (Compound) is included by Adrenergic beta1-Antagonists (Pharmacologic Class)
Carvedilol (Compound) downregulates CDC20 (Gene)
Carvedilol (Compound) causes Angina unstable (Side Effect)
Carvedilol may cause a minor interaction that can limit clinical effects when taken with Kaolin
Carvedilol may cause a minor interaction that can limit clinical effects when taken with Levothyroxine